Status:
RECRUITING
Observational Study for Patients With Hemoglobinopathies and Rare Inherited Anemia and Covid 19
Lead Sponsor:
Società Italiana Talassemie ed Emoglobinopatie
Conditions:
Haemoglobinopathies
Eligibility:
All Genders
Brief Summary
The COVID-19 pandemic is causing many deaths around the world, putting a strain on health services. Patients with pre-existing chronic conditions are most affected by the SARS-COV2 infection. Infectio...
Detailed Description
The COVID-19 pandemic is causing many deaths around the world, putting a strain on health services. Patients with pre-existing chronic diseases are most affected by SARS-COV2 infection. Italy is one o...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Patients with an established diagnosis of thalassemia, sickle cell disease, other haemoglobinopathies and Rare Anemia inherit with a virological diagnosis of SARS-COV-2 infection.
- EXCLUSION CRITERIA:
- nobody
Exclusion
Key Trial Info
Start Date :
March 31 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2030
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT04746066
Start Date
March 31 2020
End Date
December 1 2030
Last Update
May 5 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
E.O. Ospedali Galliera
Genova, Italy, 16128
2
Ospedali Galliera - S.S.D. Microcitemia, anemie congenite e dismetabolismo del ferro
Genova, Italy, 16128